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sion: Practice effects with repeated administration of neuro-
psychological tests must be accounted for in the interpreta-
tion of such tests. Ignoring practice effects may lead to an 
underestimation of POCD. The usefulness of the proposed 
demographically adjusted continuous score for cognitive 
function will have to be tested prospectively in patients. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 There is growing interest in cognitive deficits occur-
ring in the context of therapeutic interventions. In par-
ticular, elderly patients are at risk of developing such def-
icits, which can be found in a surprisingly large number 
of patients. Monk et al.  [1] have documented such chang-
es in 41% of patients aged 60 years or older after major 
non-cardiac surgery. After intensive care treatment, the 
incidence is less clear, as typically no baseline cognitive 
testing is available for patients admitted to the intensive 
care unit. However, cognitive deficits have been described 
in 30–80% of patients 6–12 months after intensive care 
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 Abstract 
 Background/Aims: Cognitive dysfunction after medical 
treatment is increasingly being recognized. Studies on this 
topic require repeated cognitive testing within a short time. 
However, with repeated testing, practice effects must be
expected. We quantified practice effects in a demographi-
cally corrected summary score of a neuropsychological test 
battery repeatedly administered to healthy elderly volun-
teers.  Methods: The Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) Neuropsychological Assess-
ment Battery (for which a demographically corrected sum-
mary score was developed), phonemic fluency tests, and 
trail-making tests were administered in healthy volunteers 
aged 65 years or older on days 0, 7, and 90. This battery al-
lows calculation of a demographically adjusted continuous 
summary score.  Results: Significant practice effects were 
observed in the CERAD total score and in the word list (learn-
ing and recall) subtest. Based on these volunteer data, we 
developed a threshold for diagnosis of postoperative cogni-
tive dysfunction (POCD) with the CERAD total score.  Conclu-
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unit discharge  [2, 3] . The diagnosis of cognitive changes 
requires repeated neuropsychological assessments with-
in a short period of time. Time intervals of 7 days and 3 
months are often used for postoperative cognitive dys-
function (POCD)  [1, 4] . Apart from the heterogeneity of 
the test batteries used to diagnose POCD, which makes 
comparisons between studies difficult, two important 
points need to be considered. First, repeated cognitive 
testing may lead to practice effects, at least in some of the 
tested domains. Ignoring practice effects may lead to an 
underestimation of the incidence of POCD, as potential-
ly not only a deterioration is relevant, but also the failure 
to show a learning curve with repeated testing may be 
indicative of a cognitive deficit. Second, the diagnosis of 
POCD is made if a patient shows a certain predefined 
grade of deterioration in the cognitive tests used. So far, 
to the best of our knowledge, only binary criteria have 
been used to define POCD. However, as already suggest-
ed by Newman et al.  [5] , postoperative cognitive changes 
are not likely to be an all-or-nothing phenomenon, but 
rather represent a continuum of subtle changes in cogni-
tive function. Accordingly, test batteries should report 
the results on a continuous scale rather than in a binary 
fashion. Furthermore, to avoid the need for comparisons 
with controls, it would be desirable to have an easy-to-use 
neuropsychological test battery that can adjust for demo-
graphic factors such as age, gender, and education.
 We quantified practice effects with repeated adminis-
tration of the extended version of the Consortium to Es-
tablish a Registry for Alzheimer’s Disease – Neuropsy-
chological Assessment Battery  [6] (CERAD-NAB, vali-
dated German version)  [7] for which a summary score 
(the CERAD total score)  [8] was calculated using healthy 
volunteers. This score ranges from 0 to 100 and poten-
tially allows cognitive dysfunction to be quantified as a 
continuous variable. Data are available that allow adjust-
ment of test results for the demographic factors age, gen-
der, and education. We also assessed the commonly used 
tests for phonemic fluency  [9] and the trail-making tests 
(TMT)  [10] for practice effects. These tests are not in-
cluded in the CERAD battery. However, they are fre-
quently used in the assessment of POCD to test attention 
and executive function. 
 Methods 
 Participants 
 This study was approved by the regional ethics committee 
(Ethikkommission beider Basel, registered at www.clinicaltrials.
gov, NCT00512200), and all participants gave written informed 
consent prior to testing. Participants were given feedback on their 
test scores if they requested it, and referral was made when pos-
sible problems were detected. Healthy volunteers aged 65 years or 
older were eligible, and recruited from the audience of a popular 
lecture series on various topics organized by the University of Ba-
sel, Switzerland, and offered specifically to elderly people irre-
spective of their educational background. Exclusion criteria were 
a history of cerebrovascular disease, a Mini-Mental State Exami-
nation (MMSE) Score  ! 24, and long-term psychiatric medication 
use. Sixty participants were included, all of whom were native 
German speakers, none of whom was institutionalized, and none 
of whom had previously met clinical criteria for dementia or mild 
cognitive impairment. All participants were administered the 
German version of the CERAD-NAB, phonemic fluency test, and 
TMT on days 0, 7, and 90. Administration of tests was standard-
ized as previously described  [6] . Additionally, the participants 
were screened for subjective symptoms of depression using the 
Geriatric Depression Scale  [11] , and autonomy was assessed with 
the Instrumental Activities of Daily Living Scale  [12] on days 0 
and 90. Education, medical history, medication, alcohol and to-
bacco consumption, and blood pressure were recorded. 
 Cognitive Function Testing 
 The German version of the CERAD-NAB is composed of 6 
subtests: 
 Verbal Fluency 
 In the verbal fluency test  [13] , impairments in verbal produc-
tion, semantic memory, and language are tested. Subjects are 
asked to name as many animals as possible in 1 min (maximum 
score = 24). 
 Boston Naming Test 
 The Boston Naming Test is a naming task where the subject is 
asked to name 15 objects presented as line drawings; a maximum 
of 10 s is allowed for each drawing (maximum score = 15)  [6, 14] . 
 Mini-Mental State Examination 
 The MMSE is a widely used and well-known brief cognitive 
battery testing immediate and delayed memory, orientation, con-
centration, language, and praxis  [15] .
 Word List Test 
 The word list test measures the ability to remember newly 
learned information (word list learning) and delayed memory 
(word list recall and word list recognition)  [16] . Ten printed words 
are presented at a frequency of 1 every 2 s, and the subject is asked 
immediately after the tenth word to recall as many of the words 
as possible. There are 2 subsequent trials in which the same 10 
words are presented in a new random order, and after each trial 
the subject is again asked to recall as many words as possible 
(word list learning, maximum score = 30, the sum of the number 
of words learned over the 3 trials). After a delay of 5–10 min (time 
taken for the constructional praxis test), the patient is asked to 
recall as many of the 10 words presented in the word list memory 
task as possible (word list recall, maximum score = 10). In the 
word list recognition test, the patient is presented with a list of 20 
printed words and asked after each word to say whether the word 
was one of the words s/he was presented with earlier in the word 
list learning test (maximum score = 10: number of true positives 
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minus number of false positives)  [6] . In accordance with Ehrens-
perger et al.  [17] , we used 2 additional variables: (1) ‘intrusions’, 
the number of word responses given in the word list learning tri-
als and the word list recall that were not in the original list, and 
‘savings’, the proportion of correctly recalled words during the 
word list recall trial compared with word list learning trial 3; (2) 
‘discriminability’, calculated by dividing the number of true pos-
itives by the number of true negatives in the word list recognition 
trial. 
 Constructional Praxis Test 
 In the constructional praxis  [18] test, the subject is instructed 
to copy 4 line drawings of increasing complexity: a circle, a dia-
mond, intersecting rectangles, and a three-dimensional cube 
(maximum score = 11)  [6] . After a delay of 5 min (time taken for 
the word list recall test), the patient is asked to again recall and 
draw as many of the line drawings as possible (constructional 
praxis recall). According to Ehrensperger et al.  [17] , ‘construc-
tional praxis savings’ was calculated as the proportion of correct-
ly recalled figures during the constructional praxis recall trial 
compared to constructional praxis.
 Phonemic Fluency and TMT 
 Phonemic fluency test (‘s’ words)  [9] and TMT (parts A and B) 
 [10] were added to the CERAD-NAB to include some tests focus-
ing upon attention and executive function. In the phonemic flu-
ency test, the patient is asked to name as many words starting with 
an ‘s’ as possible in 1 min (numbers and proper names are not al-
lowed). In the TMT part A, the subject is instructed to draw lines 
connecting circles numbered 1–25 in ascending order. In part B, 
the circles include both numbers (1–13) and letters (A–L) and the 
subject is instructed to connect the circles in an ascending pat-
tern, alternating between the numbers and letters (i.e. 1-A-2-B-
3-C, etc.). Time for completion of the test is recorded.
 All tests were administered by two authors (D.B.-B. and C.S.B.) 
who were trained and supervised by a certified psychologist 
working at our memory clinic. The tests were administered in a 
standardized fashion in a quiet room. The unadjusted CERAD 
total score was calculated as described by Chandler et al.  [8] , and 
demographic adjustment (for age, gender, and education) was 
performed according to the formula developed for the German 
version of the CERAD by Ehrensperger et al.  [17] : Chandler raw 
total score – (–0.391  ! age + 0.886  ! education + 4.447  ! gen-
der) with gender coded as male = 0 and female = 1.
 Statistical Analysis 
 Raw scores of the CERAD-NAB subtests were adjusted for age, 
gender, and years of education as previously described  [7] . To 
avoid the difficulties resulting from comparing raw test scores of 
different tests, z-scores (i.e. a dimensionless quantity indicating 
standard deviations above or below the mean) were calculated 
based on normative values from 1,100 elderly Swiss individuals 
allowing calculation of demographically adjusted (age, gender, 
and education) standard scores. For statistical analysis of practice 
effects, repeated-measures ANOVA of 16 test scores was used. To 
address the problem of multiple testing, p values of the within-
subjects factors of the repeated-measures analysis were adjusted 
according to the Bonferroni procedure. The level of significance 
derived from this procedure was 0.003 (adjusted   = 0.05/16). The 
Bonferroni-Holm procedure testing the next lower p value (0.01) 
delivered a level of significance of 0.05/(16 – 4) = 0.05/12 = 0.004. 
As no p value was between the Bonferroni limit and the Bonfer-
roni-Holm limit for the next level of significance, only the Bonfer-
roni correction was used. For any subtest that was significant in 
the Bonferroni procedure, pairwise comparisons between base-
line, day 7, and 3 months could be done without further adjust-
ment by a closed multiple-testing procedure. Regression analysis 
was used to calculate threshold values for POCD at follow-up
depending on baseline result. Statistical calculations were per-
formed with SPSS 17.0 for Windows (SPSS, Chicago, Ill., USA).
 Results 
 Sixty subjects were included and tested. Three were 
excluded from analysis, 2 because they did not complete 
all the follow-up tests and 1 because of sedatives taken 
prior to the second test. Characteristics of the remaining 
57 participants are shown in  table 1 .
 Tests were performed at baseline and were repeated 
after 7 (range 6–7) and 91 (range 81–123) days (medians).
 Results of the unadjusted and demographically adjust-
ed CERAD total score and the subtests are shown in  ta-
ble 2 .
 The p values for differences in the CERAD total score, 
CERAD subtests, phonemic fluency, and the TMTs are 
shown in  table  3 . Significant practice effects were ob-
served when results of the unadjusted and the adjusted 
Table 1. C haracteristics of participants (n = 57)
Age, years 72 (65–89)
Males 30 (53)
Education, years 14 (9–20)
Diabetes mellitus 0
Arterial hypertension 25 (44)
Cardiac disease 7 (12)
Atrial fibrillation 2 (4)
Chronic pulmonary disease 0
Peripheral vascular disease 1 (2)
Treatment with statins 7 (12)
Current smoker 6 (11)
Nicotine, pack years 4 (0–70)
Alcohol consumption, glasses/week 6 (0–28)
MMSE (baseline) 30 (26–30)
CERAD total (baseline) 91 (62–100)
CERAD total (baseline adjusted) 105 (73–115)
IADLS (baseline) 8 (8–8)
GDS (baseline) 1 (0–10)
D ata presented as n (%) or medians (range).
IADL = Instrumental Activities of Daily Living Scale; GDS = 
Geriatric Depression Scale.
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Table 2. T est results of participants (n = 57)
Baseline score Score on day 7 Score at 3 months
CERAD total score (raw) 91 (62–100) 96 (76–100) 98 (67–100)
CERAD total score (adjusted) 105 (73–115) 109 (91–118) 109 (82–121)
Semantic fluency 24 (13–32) 25 (13–40) 25 (13–39)
Boston naming test 15 (11–15) 15 (13–15) 15 (14–15)
MMSE 30 (26–30) 30 (28–30) 30 (27–30)
Word list (learning)a 25 (12–30) 29 (16–30) 29 (16–30)
Word list (recall) 9 (2–10) 10 (4–10) 10 (2–10)
Word list (intrusions)b 0 (0–4) 0 (0–4) 0 (0–2)
Word list (savings)c 100 (40–125) 100 (67–114) 100 (40–125)
Word list (discriminability)d 100 (85–100) 100 (90–100) 100 (90–100)
Constructional praxis (copy) 11 (8–11) 11 (8–11) 11 (9–11)
Constructional praxis (recall) 10 (6–11) 11 (6–11) 11 (1–11)
Constructional praxis (savings)e 100 (55–125) 100 (60–125) 100 (10–111)
Phonemic fluency 14 (5–33) 17 (6–30) 17 (6–31)
TMT (part A) 42 (21–84) 40 (20–96) 40 (21–87)
TMT (part B) 88 (39–203) 86 (33–162) 81 (42–207)
TMT (B/A) 1.96 (1–4) 1.93 (1–4) 2.00 (1–4)
D ata presented as medians (ranges).
a Sum of words learned after the 3 word list learning trials. 
b Word responses given in the word list learning trials and word list recall that were not in the original list. 
c Proportion of correctly recalled words during the word list recall trial compared with word list learning trial 3. 
d Number of true positives divided by the number of true negatives in the word list recognition trial. 
e Proportion of correctly recalled figures during the constructional praxis recall trial compared with constructional praxis.  
Table 3. D ifferences in adjusted CERAD total score and subtests expressed as p values (n = 57,  = 0.003125)
Repeated-measures
ANOVA
Baseline to
day 7
Day 7 to
3 months
Baseline to
3 months
CERAD total score <0.001 <0.001 0.109 <0.001
Semantic fluency 0.024 0.011 0.379 0.070
Boston naming test 0.244 0.182 0.871 0.230
MMSE 0.547 0.457 0.210 0.728
Word list (learning)a <0.001 <0.001 0.041 <0.001
Word list (recall) <0.001 0.012 0.022 <0.001
Word list (intrusions)b 0.270 0.643 0.230 0.096
Word list (savings)c 0.126 0.516 0.147 0.043
Word list (discriminability)d 0.350 0.903 0.151 0.161
Constructional praxis (copy) 0.070 0.523 0.103 0.037
Constructional praxis (recall) 0.011 0.097 0.280 0.006
Constructional praxis (savings)e 0.120 0.157 0.938 0.101
Phonemic fluency 0.002 <0.001 0.338 0.018
TMT (part A) 0.402 0.574 0.510 0.214
TMT (part B) 0.257 0.107 0.484 0.369
TMT (B/A) 0.533 0.365 0.289 0.764
a  Sum of words learned after the 3 word list learning trials. 
b Word responses given in the word list learning trials and the word list recall that were not in the original list. 
c Proportion of correctly recalled words during the word list recall trial compared with word list learning trial 3. 
d Number of true positives divided by the number of true negatives in the word list recognition trial. 
e Proportion of correctly recalled figures during the constructional praxis recall trial compared with constructional praxis. 
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CERAD total score and word list (learning) tested on day 
7 and after 3 months were compared to baseline test re-
sults. In the subtest word list (recall), a significant prac-
tice effect was observed comparing results at baseline and 
after 3 months. With phonemic fluency, a significant 
practice effect was observed comparing results at base-
line and at day 7. In the remaining subtests, no significant 
practice effects were found when considering 0.003 as the 
level of significance.  Figures 1–3 show the histograms for 
the differences in test performance between baseline, day 
7, and 3 months (i.e. day 90) using the adjusted CERAD 
total score.
 Based on these results from healthy volunteers, we de-
veloped a diagnostic cutoff for the adjusted CERAD total 
score after 7 days and after 3 months that can be used to 
define POCD. This cutoff is dependent on changes from 
baseline and, thus, takes practice effects into account. As 
the adjusted CERAD total score is already demographi-
cally adjusted, raw data values can be used and calcula-
tion of z-scores is not necessary. Regression analysis for 
test results after 7 days and after 3 months compared to 
baseline scores resulted in the lower 10% tolerance lines 
shown in  figures 4 and  5 , and POCD can be said to be 
present if test results of an individual lie below this line. 
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 Fig. 1. Histogram for the differences in test performance between 
day 0 (baseline) and day 7 using the unadjusted CERAD total 
score (mean = 5.0, SD = 4.3, n = 57). 
 Fig. 2. Histogram for the differences in test performance between 
day 0 (baseline) and day 90 using the unadjusted CERAD total 
score (mean = 5.8, SD = 5.8, n = 57). 
 Fig. 3. Histogram for the differences in test performance between 
day 7 and day 90 using the unadjusted CERAD total score
(mean = 0.8, SD = 4.6, n = 57). 
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Excluding 2 influential observations on the left margin 
yields a less steep line and 4 instead of 5 observations be-
low it. We decided to keep these observations in the anal-
ysis. To give an example how to use the equation of the 
10% tolerance lines: first, we assume that a patient scored 
113 points in the adjusted CERAD total score at baseline 
(BL), 108 points on day 7, and 112 points at 3 months. Fill-
ing in the values for BL = 113, the equation day 7 = 47.72 
+ 0.5852  ! BL – 1.28  ! 3.39 = 43.38 + 0.5852  ! BL yields 
the result: day 7 = 110. Accordingly, the subject is expect-
ed to score at least 110 points on day 7 but only scored 108, 
and hence we assume that this patient has a cognitive def-
icit. Otherwise stated, inserting the BL score for the 
CERAD total score into the equation for day 7 or for 3 
months will return the minimal score a patient has to 
achieve on day 7 or at 3 months in order to be considered 
not to have developed a cognitive deficit.
 Discussion 
 Repeated administration of the CERAD-NAB, phone-
mic fluency, and TMT in healthy volunteers showed sig-
nificant practice effects in the CERAD total score and in 
the word list subtests (learning and recall), but not in the 
other subtests. With phonemic fluency (‘s’ words), prac-
tice effects were also found, but only on day 7 and not at 
3 months. No improvement was possible in some subtests 
due to a ceiling effect – MMSE, Boston Naming Test, and 
figures (copy) – because at baseline 97% of participants 
reached MMSE scores  6 29 of a maximum of 30 points 
and  6 14 of a maximum of 15 points on the Boston Nam-
ing Test, and 89%  6 10 of a maximum of 11 points on 
constructional praxis (figure copying). We did not per-
form a sample size calculation or define a primary out-
come parameter, as the aim of the study was exploratory; 
we wanted to quantify learning effects.
 Internationally, one of the most widely used batteries 
of neuropsychological tests is the one by the CERAD. It 
has established itself as the standard in the evaluation of 
dementia syndromes in memory clinics, at least through-
out German-speaking Europe. The CERAD-NAB assess-
es a wide variety of cognitive functions, is easy to admin-
ister after appropriate training (also by non-psycholo-
gists), is standardized, and there are normative values for 
normal controls from the CERAD registry  [6, 8, 19] and 
from several observational and longitudinal studies  [20–
22] , and from 1,100 elderly Swiss individuals allowing 
calculation of demographically adjusted (age, gender,
and education) standard scores  [17, 23] . Apart from En-
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 Fig. 4. Lower 10% tolerance line for adjusted CERAD total score: 
day 7 = 47.72 + 0.5852  ! baseline – 1.28  ! 3.39 = 43.38 + 0.5852 
 ! BL. Solid line = Estimated hyperbola; dashed line = approxi-
mated straight line. 
 Fig. 5. Lower 10% tolerance line for adjusted CERAD total score: 
3 months = 62.2 + 0.4568  ! baseline – 1.28  ! 4.27 = 56.73 + 
0.4568  ! baseline. Solid line = Estimated hyperbola; dashed
line = approximated straight line. 
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glish and German, the CERAD-NAB has been translat-
ed into several languages and validated in different cul-
tures  [24–32] . This potentially allows defining POCD as 
a change in cognition based on demographically adjusted 
data. The validated German version of the CERAD-NAB 
is an exact translation of the English original and is usu-
ally completed in 30–45 min. The tests selected for the 
CERAD battery not only measure the primary cognitive 
manifestations of Alzheimer’s disease across a range of 
severity of the disorder, but also discriminate well be-
tween normal subjects and those with mild or moderate 
dementia  [6] . This battery also has a good specificity to 
detect minor deficits such as mild cognitive impairment 
in memory and practice in healthy subjects  [33] and is, 
thus, potentially suitable for the diagnosis of POCD. The 
English version has been shown to have good interrater 
reliability (correlation coefficients from 0.92 to 1.0), lon-
gitudinal validity, and test-retest reliability, although 
normal controls tend to score at or near the maximum 
(‘ceiling effect’) in some subtests  [6, 16, 19, 34] . A sum-
mary score for the CERAD battery ranging from 0 to 100 
has been developed  [8] , and this continuous ‘CERAD to-
tal score’ has been shown to be highly accurate in differ-
entiating independent samples of normal controls, pa-
tients with minimal cognitive impairment, and Alzhei-
mer’s disease  [35] , again suggesting that this battery may 
be suitable to diagnose POCD and other cognitive defi-
cits following medical treatment or interventions. The 
cutoff differentiating normal controls from mild cogni-
tive impairment was calculated to be 85 points in the ad-
justed CERAD total score  [8] . The rationale for adding 
phonemic fluency and TMTs to the CERAD-NAB is the 
fact that tests for attention and executive function are not 
well represented in the CERAD-NAB. 
 Practice effects with repeated administration of neu-
ropsychological tests have been reported for a variety of 
tests and after various time intervals in adults and chil-
dren, as well as in brain-injured patients  [23, 36, 37] . Prac-
tice effects may be due to increased familiarity with test-
taking procedures, test-taking strategies, fewer feelings of 
fear or nervousness, a reduced sense of novelty at the time 
of retest, so-called test sophistication  [38] , and remem-
bering specific test items. While the issue of remember-
ing test items is likely to be more pronounced if the test 
is repeated after a short interval  [39] , test sophistication 
may be responsible for practice effects occurring with an 
interval between successive tests as long as 2–3 years.
 With the German version of the CERAD-NAB,
healthy volunteers showed statistically significant prac-
tice effects in verbal learning (word list) and visual mem-
ory – constructional praxis (savings) – after 2.4  8 0.28 
years, whereas there were no practice effects found in se-
mantic fluency, Boston Naming Test, and constructional 
praxis (delayed recall of figures)  [23] . As it is unlikely that 
specific test items were memorized for more than 2 years, 
the authors suppose that the observed improvement was 
due to test sophistication  [38] .
 There are some limitations to our approach. The inter-
pretation of our results may be limited by a recruitment 
bias. Healthy and motivated individuals are more likely 
to volunteer for a research project. Our study population 
may not necessarily be different from a group of patients 
as far as age and education are concerned, but concerning 
baseline cognitive function, mobility, independence, and 
possibly also scores on the geriatric depression scale. Fur-
thermore, the good performance of the participants made 
it impossible to detect practice effects in subtests with so-
called ceiling effects, because near maximum scores left 
no room for improvement in the repetition of these sub-
tests. However, the CERAD total scores of some volun-
teers were quite low, suggesting that the investigated vol-
unteers might represent the elderly population at large. 
Using the cutoff score of 85 of the adjusted CERAD total 
score  [8] , 3 of our volunteers could be diagnosed with a 
cognitive impairment. The CERAD-NAB and, thus, the 
CERAD total score do not include adequate tests for as-
sessing attention span and executive function, which may 
also be important issues in POCD. Therefore, we added 
phonemic fluency and TMTs to the CERAD-NAB. How-
ever, the results of both phonemic fluency and TMTs are 
missing from the CERAD total score, and it would be de-
sirable to have them included. On the other hand, admin-
istration of the CERAD-NAB, phonemic fluency test, 
and TMT takes 40–55 min. If time is critical, the CERAD-
NAB could possibly be shortened to include word list 
learning and word list recall separated by an intervening 
task. Using a Bonferroni correction with   = 0.003 may 
be a conservative approach, but we think it is appropriate. 
If the Bonferroni correction were ignored (i.e. using an
  = 0.05), additional practice effects in the subtests word 
list (learning) (comparing scores on day 7 and at 3 
months), word list (recall) (comparing scores at baseline 
and on day 7 and scores on day 7 and after 3 months), and 
phonemic fluency (comparing scores at baseline and after 
3 months) would be statistically significant. The 2 addi-
tional subtests, in which statistically significant practice 
effects would be observed ignoring the Bonferroni cor-
rection, are semantic fluency (comparing scores at base-
line and day 7) and figure (recall) (comparing scores at 
baseline and after 3 months). 
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